Abaxis
Point-of-care device manufacturer Abaxis and biosensor firm LamdaGen said this week that they have entered into an R&D agreement aiming to integrate LamdaGen's plasmonic ELISA technology on Abaxis's rotor-based POC platforms.
Cepheid to Pay Abaxis $17.25M to Settle Infringement Case
NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Tuesday that it has reached a settlement with Abaxis over litigation the firms had filed against each other a couple of yeasr ago.
Abaxis claims that Cepheid's PCR-based blood test for methicillin-resistant Staphylococcus aureus infringes its sample prep patents. In response, Cepheid has filed a counterclaim denying the alleged infringement and asking the court to find that Abaxis' patents are invalid.
Cepheid Files Countersuit against Abaxis in Reagent Patent Dispute
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.